Anti-eNOS Antibody, clone 2F12 ZooMAb® Rabbit Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone 2F12 is a ZooMAb® rabbit recombinant monoclonal antibody that specifically detects endothelial nitric oxide synthase (eNOS). It targets an epitope within 16 amino acids from the Flavodexin-like domain.
• Immunogen: KLH-conjugated linear peptide corresponding to 16 amino acids from the Flavodoxin-like domain from the Internal region of human eNOS.
• Application: Quality Control TestingEvaluated by Western Blotting in Rat Spleen tissue lysate.Western Blotting Analysis: A 1:1,000 dilution of this antibody detected eNOS in Rat Spleen tissue lysate.Tested ApplicationsAffinity Binding Assay: A representative lot from a representative lot bound eNOS peptides with a KD of 3.3 x 10-8 in an affinity binding assay.Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected eNOS in human placenta tissue sections.Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected eNOS in HUVEC and HepG2 cells.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
• Target description: Nitric oxide synthase, endothelial (UniProt: P29474; also known as EC:1.14.13.39, Constitutive NOS, cNOS, EC-NOS, Endothelial NOS, eNOS, NOS type III, NOSIII) is encoded by the NOS3 gene (Gene ID: 4846) in human. NOS is known to exist in three forms (a) a soluble, constitutively expressed enzyme found in high concentrations in the brain (nNOS or NOS-1), (b) a constitutively expressed endothelial membrane bound enzyme (eNOS, NOS-3), and (c) an inducible enzyme (iNOS or NOS-2) that is associated with the cytotoxic function of macrophages. They exhibit similarities in their structure and mechanism of action. Calmodulin is required for the activity of all three isoforms. All NOS are single polypeptides that differ in their rates of Nitric oxide ( NO), Ca2+- dependence, cytochrome c reduction, and NADPH utilization. For their catalytic activities NOS isoforms require three distinct domains: (a) a reductase domain, (b) a calmodulin-binding domain, and (c) an oxygenase domain. The reductase domain contains the FAD and FMN moieties. The oxygenase domain catalyzes the conversion of L-arginine to citrulline and NO. The eNOS is mainly expressed in vascular endothelial cells and cardiomyocytes. The NO produced by the eNOS in endothelial cells acts as a vasodilator and regulates blood flow and blood pressure. In cardiac cells, eNOS is expressed in response to shear stress, exercise, chronic hypoxia, and cardiac failure. In endothelial cells, eNOS is localized in specialized plasmalemmal pockets known as caveolae, which contain a scaffolding protein termed caveolin. Acylation of eNOS by either myristate or palmitate targets it to caveolae, which facilitates enzyme activation following receptor stimulation. In a resting cell, eNOS is inhibited by its interaction with caveolin. Following agonist activation, eNOS dissociates from caveolin and translocates to the cytosol. The eNOS is generally activated in response to an increase in intracellular Ca2+ following stimulation with receptor-dependent agonists such as acetylcholine. However, shear stress can also activate this enzyme, independently of Ca2+ level changes, via a tyrosine kinase-dependent mechanism involving its phosphorylation and redistribution. Low concentrations of NO in the endothelial cells prevent their apoptotic death and maintain their integrity during inflammation and atherosclerosis. Distorted production of NO in endothelial cells has been linked to hypertension, hypercholesterolemia, diabetes, and even cardiac failure. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.
• Physical form: Purified recombinant mouse monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
• Reconstitution: 300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.